New radioactive therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07567521

Recruiting now Disease control Sponsor: C Ray Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to kill them. The trial will enroll 90 participants to evaluate safety, dosing, and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRC003 (a radioactive molecule that targets and kills prostate cancer cells)
What this could lead to: If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 90 participants, so it is not yet proven to be safe or effective. Radioactive treatments can cause side effects like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital
RECRUITING

Taiyuan, Shanxi, 030013, China
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.